Literature DB >> 15649858

German-Austrian recommendations for the antiretroviral therapy of HIV-infection (status May 2004).

B Salzberger1, U Marcus, B Vielhaber, K Arasteh, J Gölz, N H Brockmeyer, J Rockstroh.   

Abstract

The availability and application of effective antiretroviral combination therapies have now almost become routine. More than 20 antiretroviral substances in four classes have been approved. Although an almost incalculable number of combinations can be conceived, it must be stressed, that only a small number of the theoretically possible combinations are actually applicable. As a result of the broad therapeutic armamentarium, HIV infection can be better treated. However, the decisions to start, monitor and change therapy have become even more difficult because the indication for treatment, the selection of the most suitable therapy for an individual, the information and counselling of the patient, and the monitoring of the success of treatment all demand a high level of knowledge and experience. This guideline evaluates the indication and selection of the initial antiretroviral therapy for HIV infection.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15649858

Source DB:  PubMed          Journal:  Eur J Med Res        ISSN: 0949-2321            Impact factor:   2.175


  9 in total

1.  Antiretroviral therapeutic drug monitoring in Canada: current status and recommendations for clinical practice.

Authors:  Niamh Higgins; Alice Tseng; Nancy L Sheehan; Charles J L la Porte
Journal:  Can J Hosp Pharm       Date:  2009-11

Review 2.  [HIV-related symptoms].

Authors:  A Potthoff; N H Brockmeyer
Journal:  Urologe A       Date:  2006-12       Impact factor: 0.639

3.  The rainbow cohort: 96 week follow-up of saquinavir-containing regimens in previously antiretroviral therapy (ART)-naive and pre-treated but protease inhibitor (PI)-naive HIV-infected patients.

Authors:  H Knechten; C Stephan; F A Mosthaf; H Jaeger; A Carganico; T Lutz; K Schewe; C Mayr; E Wolf; E Wellmann; A Tappe
Journal:  Eur J Med Res       Date:  2011-03-28       Impact factor: 2.175

Review 4.  [Antiviral treatment regimens].

Authors:  S Esser
Journal:  Hautarzt       Date:  2006-11       Impact factor: 0.751

5.  Safety and efficacy after switch to a saquinavir-containing antiretroviral regimen in protease inhibitor pretreated HIV-positive patients.

Authors:  C Stephan; H Jaeger; A Carganico; G Knecht; T Lutz; C Mayr; F A Mosthaf; S Koeppe; M Mueller; E Wolf; A Tappe; E Wellmann; H Knechten
Journal:  Eur J Med Res       Date:  2010-09-24       Impact factor: 2.175

6.  The timing of introduction of pharmaceutical innovations in seven European countries.

Authors:  Ragnar Westerling; Marcus Westin; Martin McKee; Rasmus Hoffmann; Iris Plug; Grégoire Rey; Eric Jougla; Katrin Lang; Kersti Pärna; José L Alfonso; Johan P Mackenbach
Journal:  J Eval Clin Pract       Date:  2014-04-22       Impact factor: 2.431

7.  Prevalence and effect of pre-treatment drug resistance on the virological response to antiretroviral treatment initiated in HIV-infected children - a EuroCoord-CHAIN-EPPICC joint project.

Authors:  Nicole Ngo-Giang-Huong; Linda Wittkop; Ali Judd; Peter Reiss; Tessa Goetghebuer; Dan Duiculescu; Antoni Noguera-Julian; Magdalena Marczynska; Carlo Giacquinto; Luminita Ene; Jose T Ramos; Cristina Cellerai; Thomas Klimkait; Benedicte Brichard; Niels Valerius; Caroline Sabin; Ramon Teira; Niels Obel; Christoph Stephan; Stéphane de Wit; Claire Thorne; Diana Gibb; Christine Schwimmer; Maria Athena Campbell; Deenan Pillay; Marc Lallemant
Journal:  BMC Infect Dis       Date:  2016-11-08       Impact factor: 3.090

8.  [Treatment management of a multiply injured patient with HIV infection].

Authors:  C Mand; K Giannadakis; M Schnabel; R Stiletto
Journal:  Unfallchirurg       Date:  2007-11       Impact factor: 0.918

9.  German-Austrian recommendations for HIV1-therapy in pregnancy and in HIV1-exposed newborn, update 2008.

Authors:  Bernd Buchholz; Matthias Beichert; Ulrich Marcus; Thomas Grubert; Andrea Gingelmaier; Annette Haberl; Brigitte Schmied
Journal:  Eur J Med Res       Date:  2009-11-03       Impact factor: 2.175

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.